Login to Your Account



Word Up: Lexicon's Carcinoid Phase II Good, Phase III Starts

By Randy Osborne
Staff Writer

Monday, October 15, 2012
A successful, earlier-stage trial with its oral, serotonin-reducing therapy for carcinoid syndrome helped Lexicon Pharmaceuticals Inc. figure out dosing in a Phase III study, the start of which made news at the same time that the company disclosed results from the Phase II experiment with LX-1032, or telotristat etiprate.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription